My name is Dylan Jovine.

What I’m about to share with you may sound like it's right out of a Star Trek episode.

But make no mistake about it: this medical revolution is happening right now. In real time.

Don’t just take my word for it.

60 Minutes reported that this treatment could be “the most consequential discovery in biomedicine this century.”

Hyperbole aside, I believe this one treatment will change what it means to get sick.

Not for our generation. We’re too old. But for our kids. And grandkids.

Now, what I’m saying to you may sound extreme. And maybe you doubt my predictions, which is fine.

But please know that people doubted me when I predicted the Great Recession and market crash a year before it happened.

A year later, the S&P 500 dropped 47%...

They doubted me when I predicted a big stock rally during the height of the Covid panic…

Six months later, the market was up 60%.

When in July of 2021, I predicted Russia and China would bring the world into a new cycle of war.

…just seven months before Russia invaded Ukraine.

When in 2022, I predicted that inflation would last longer than expected.

A lot of people laughed at me when I made these predictions.

They didn’t think a kid who grew up dirt poor and went to city college could ever know more than the “Elites.”

Both Google & Facebook suspended my accounts.

And even the Chinese Communist Party sent a woman to talk to me when I first warned America that China wanted to take Taiwan and control the future of AI.

But despite the risks to my business, I didn’t let any of them stop me from getting you the truth.

I fought on to keep bringing you the most important financial stories nobody else was talking about.

And I’ll never stop.

In the wake of predicting the real estate collapse a year before it happened, I was interviewed by Fox Business…

And then I was invited to Washington, D.C. to meet President George Bush…

...and Vice President Dick Cheney.

And more recently, I made waves when…

I predicted that Ukraine would master A.I. to stand a chance against a larger and more powerful Russia.

Now Ukraine is now considered a global leader in robot warfare…

And it was recently reported that drones now do 70% of the fighting in the war.

But I didn’t just make these predictions to hear myself talk.

I showed my readers the best ways to capitalize on this, like:

Palantir for 362% gains in eighteen months…

C3.ai for 133% gains in five months…

And IONQ for 431% gains in seven months…

Yes, it is true that these are some of my most extraordinary plays.

But we’re an extraordinary service.

We launched our service in January of 2018, almost eight years ago.

From when we launched through May 30, 2025, we’ve achieved a 75.2%-win rate on all closed trade recommendations…

And over those eight years, we’ve delivered a 43.8% AVERAGE RETURN across both winners and losers.

That’s not HYPE. That’s not SALES PITCH. That’s FACT.

Those excellent returns have come during regular bull markets and bear markets, during inflation and trade wars…

But none of that compares to the historic opportunity I see coming from the “Holy Grail” of medicine…

Now to be perfectly clear…

I’m no stranger to capitalizing on big megatrends.

In fact…

That’s 30 opportunities for investors to double their money…

Folks who followed my past plays could have been ahead of all these opportunities themselves…

Instead of watching from the sidelines while everyone else got rich.

I get so much joy out of receiving letters from readers who listened and took action on my predictions…

Like this one from Judi…

Or this one from Harry H…

Here’s one from Daniel P…

Now I don’t say all this to brag.

I say it to show you that I've been making money for myself and my clients for over 30 years now.

This ain’t my first rodeo.

It’s one of those “once-in-a-generation” kind of opportunities… giving you the chance to earn "once-in-a-generation" profits.

And that brings us to today.

So how does a guy who built his reputation on making bold and timely predictions get involved with biotech stocks?

In 2013, I became sick. I won’t mention the details in public, but let’s just say the sickness almost destroyed my life.

My work began to suffer.

I just couldn’t think straight. I couldn’t put my thoughts together. Partners and employees started to work around me.

It didn’t matter that I was the Founder & CEO of a company. I was a sick man and was treated as such.

I could barely focus, let alone run a company. All I wanted to do is sleep all day. So that’s what I did.

It wasn’t long before I had to resign from the company I founded. Thankfully, I had enough money to retire.

Two years and many doctors later, I found one who helped. He asked if I’d be interested in enrolling in an experimental gene-therapy program that custom-tailors treatments based on my genetic profile.

Instead of chemical medicines, he would recommend customized treatments based on my personal test results. I was so desperate I agreed.

We’ve made a dozen or so adjustments like that based on my genetic profile and I slowly started to get well. A year or so later I started to feel like my old self again.

And then the investor in me took over. I started asking questions.

What company was behind these genetic tests? Is the company publicly traded? What other companies do this? What else do they treat? Are they publicly traded?

And who else knows about this?

Nobody did.

It was like a secret bull market happening in my bathroom – and it was staring me in the face when I brushed my teeth in the morning.

But it seemed nobody was talking about it, outside of a small group of scientists and investors. Nobody.

That was in 2016.

In April 2018, I decided to do something a bit crazy: I came out of retirement to let people know about the biotech stocks I liked, so they know exactly which ones to buy, when to buy and when to sell.

In a moment, I'll show you how you can join them.

But first let me explain why this opportunity is so unique… and why both big business and government are rushing to seize the opportunity.

It’s because this opportunity reminds the smart money of one of the biggest successes in biotech history: Amgen.

Amgen stock has risen 46,751% since 1987.

What launched that tremendous run was one drug Amgen created: Epogen. Epogen is used to treat one illness – anemia in Kidney Patients.

This revolutionary new treatment has the potential to treat all 6,000 genetic diseases, not just one.

I think this opportunity could do the same for you without having to invest in options or take unnecessary risk.

Once you have a strong patent it’s like owning a toll bridge. Everyone who wants to pass by has to pay you a toll.

Remember, most biotech companies are started and run by scientists and academics.

What do these guys know about the business of selling drugs around the globe?

The last ingredient is by far the rarest and most special. You won’t find it with every biotech but when you do you know you’re on the right path.

If someone challenges your patent that means they consider it valuable. And if you win that’s a big deal!

Using these ingredients as a framework allowed me to recommend Immunogen to my readers at $5.30 per share.

Just eighteen months later, the company was taken over at $31.26 per share for a 430% gain.

Or ChemoCentryx, which rose 435% from my recommend price.

Or Krystal Biotech, which rose 27% from my recommended price.

Of course, the trick is knowing if the underlying science is real and if the patents behind it are valid.

That’s why I’ve spent so much time developing this network of scientists and doctors – I want to know about the science directly from the horse’s mouth. Or directly from the friends and colleagues of the horse.

Again, there are 6,000 genetic diseases that we know of. And so far, we’ve only developed 300 drugs to deal with them. And those drugs come with significant side effects.

And what makes this treatment so unique is that it has the potential to cure all of them.

The contents of this vial will change medicine and perhaps what it means to be human - I’ve never been more certain of anything in almost thirty years as a professional investor.

So what is this breakthrough that’s going to revolutionize medicine?

How on earth does the liquid in this one vial have the potential to cure all 6,000 genetic diseases known to man?

In short, it’s a treatment that eliminates the need for medicine as we currently know it.

It’s called CRISPR for short.

Let me explain…

But like all drugs, MiniPress is a chemical compound. And taking it means you’re putting something with a chemical structure into your body.

Now the first thing you hope for when taking any chemical-based medicine is that it works.

The second thing you hope for is that the side effects aren’t overwhelming. And finally, if all the above check out you pray that you don’t develop a tolerance for the chemical, and it stops working.

And if the medicine you’re prescribed doesn’t work you have to contemplate the worst-case scenario which is chemo and then surgery. Or, sometimes surgery then chemo.

Each new option is an order of magnitude worse than the last one.

With few exceptions, that’s the way medicine has worked for the better part of the past century. Doctors diagnoses a problem, prescribes a drug and you call it a day.

But in recent years we’ve learned that behind prostate cancer is a genetic mutation.

You’re either born with it, meaning you inherit it from your folks. Or you develop it during your life, meaning you had some genetic predisposition to it and perhaps the environment you were in or other factors lead to it expressing itself.

But if we now know the specific mutation causing the disease, why not replace the sick DNA with some healthy DNA?

The new CRISPR technology does just that…

CRISPR allows scientists to tell a cell to go into your DNA and find the place where the mutation matches.

And once it gets to the place it cuts the DNA and provides the sequence with a repair sequence.

So that by the time you’re finished you’re left with a normal, healthy DNA sequence.

In simple terms, CRISPR technology is on the verge of making the medicines we all grew up with obsolete.

And that means that the genetic mutation that caused the prostate cancer you originally went to the doctor for is made normal.

Diseases like these would become a thing of the past. Future generations would learn about them by reading about them in the history books.

The implications of this is mind-boggling…

As 60 Minutes put it, it could be “the most consequential discovery in biomedicine this century.”

If all of this sounds like something out of a SCI-FI movie, consider this…

The very same technology is now being used to accomplish this…

These 3 examples are just the tip of the iceberg…

Every industry is starting to implement this new technology… as the MIT Technology Review said best, “Big Pharma Doubles Down on CRISPR.”

We are at the beginning of this revolution.

And this is just the beginning of what could be a very profitable ride for early investors.

The market for this treatment will grow beyond anything we’re used to.

CRISPR is to the drug industry what the iPhone was to the old cell phone: fasten your seatbelt because things are about to change very quickly.

Walmart revolutionized mass discount shopping, which sent shares up 23,900%.

Google revolutionized search, which sent shares up 11,385%.

And that’s the reward facing early investors in CRISPR.

Which is why the biggest, smartest, most informed investors on Wall Street are flocking to invest in this also.

I already mentioned Bill Gates and Google Ventures.

And I pointed out that the largest drug companies have invested billions of dollars into this treatment during the past year alone.

But the Wall Street firms also investing read like a “Who’s Who” of making money: firms like BlackRock, JP Morgan Chase, Goldman Sachs, Morgan Stanley, Loomis Sayles.

The list goes on and on. It reads like a who’s who of the smartest VC firms on earth.

It comes down to this…

But here’s the thing…

As remarkable as these gains are…

They don’t compare to what’s in front of us right now as we shift toward CRISPR-based medical treatment.

And while there will be several ways to profit in the coming years, there will not be an opportunity like the one before you today.

You see, the dawn of a new medical age is upon us.

This is the very beginning.

I am confident investors with the foresight to invest in the right companies during the CRISPR revolution – before the general public realizes how big this opportunity is - will be rewarded with returns similar to these.

In other words, the cells themselves are like the hardware. What we tell them to do is like the software.

And that’s why investing in the right software company could mean life-changing profits.

Listen: We are witnessing the launch into an amazing new age of medicine, the likes of which the world has never seen before. That age, above everything else, is being driven by gene-based therapies.

Gene-based therapies will literally change your relationship with your doctor.

Imagine not having to take a half-dozen or so different pills every day?

Imagine a world with no side-effects?

That’s literally what we’re talking about here.

It’s no wonder that the journal Nature said, “Gene editing is quietly revolutionizing the search for new drugs.”

Wired magazine said CRISPR could “fundamentally transform our power over nature.”

So, to get in on the action, you will want to own a company that programs those CRISPR cells.

But here’s the thing…

I’m not recommending any of the big companies.

For the folks who follow my research, I prefer recommending biotech’s on the very forefront of this massive change. The biotech’s that the large companies are partnering with.

That’s where all the innovation is. And that comes in the form of smaller companies with the world’s leading scientists.

My research has led me to a firm that was formed five years ago. And this small company has the one thing that matters the most: the patent on the most popular way of doing this.And they have the two other key ingredients: a strategic partner and they survived a patent challenge.

In the last few months, they’ve announced positive results from a partnership with Allergan Pharmaceuticals and Celgene, one of the largest biotech companies in the world. Both of whom would also be natural acquirers.

And even if a small part of the $2 trillion market flows toward this small cap firm, the growth will be through the roof.

Amgen made investors 46,750% percent in part because Medicare pays them $2 billion a year for one drug.

As far as opportunities go, we’re comparing apples to oranges here.

To give you an edge, I’ve put all the details in a special report called “Living Software - The Small Company Revolutionizing Medicine.”

This report tells you everything you need to know about this incredible company and why the world’s leading scientist believes its CRISPR technology is the best, giving you the chance to ride the biggest revolution in medicine.

I will give it to you for free at the end of this letter.

Again, the CRISPR revolution is in its infancy. Most people I talk to have never even heard of it - yet.

Which is why the smart money is pouring so much into this idea. By the time your neighbor is talking about it, it’s going to be too late.

And this is the companies best position to capture the bulk of the upside.

I have no doubt, if you invest in this company today, you give yourself the opportunity to make the kind of money that lets you put your name on a building.

There is no time to waste. The biggest obstacle preventing this stock from returning 46.750% is that it gets acquired by one of the major pharma companies it has deals with.

Again, my report “Living Software - The Small Company Revolutionizing Medicine” is yours absolutely free.

But I’ve worked on Wall Street and been in the game for almost thirty years. I’ve heard every hustle in the book. So, I’m thinking either they’re hustling me, or they get lucky.

So, I’m skeptical. Anyone can get lucky.

Then I read about another stock, Puma Biotechnology, which also goes up 452% in twelve months.

And then finally, after Lannett soars 1,260% in two years I think to myself there’s something special happening in biotech.

You know how much money I made with these three stocks?

Not a single penny. And that hurt. It always hurts to know about big gains you could have made but didn’t.

But I wasn’t skeptical anymore.

And it’s that experience that has led me to start an investment advisory service called Behind the Markets.

This investment service allows you to look over my shoulder at what I’m buying and selling each and every single month. Basically, I’m sharing my rolodex of scientists and doctors with you.

As soon as you become a member of Behind the Markets, you become part of my “inner circle” – just like my mother – and you’ll get access to every single investment opportunity I discover each month.

As a member of Behind the Markets you’ll receive:

But most importantly, once you join Behind the Markets, you get access to yours truly – me.

Like my own family and friends, from now on you’ll know about the big opportunities like this CRISPR stock early, when the rest of the smart money learns about them. By the time the general public starts buying shares, it will be us selling our stock to them.

You’ll also know EXACTLY what to buy or what to sell or what to do when the market crashes, like it did in 2009.

If you can check those three boxes, you’ll inevitably find companies with outsized potential…

It’s this philosophy which led me to the special biotech stock we’ve discussed today…

And has helped my newsletter, Behind the Markets, crush every benchmark since inception.

In fact, we’ve nailed a win rate of 3 out of every 4 trades for 8 years running…
With some serious home runs.

Like the 188% on Viking Therapeutics in less than a year.

The 114% gain from ON Semiconductor in 3 years.

The 250% on Scotts Miracle Gro in about 2 years.

The 339% on IntelSat in 4 months…

The list goes on.

But all of them went through the same selection process… which is why I am so confident in this small biotech stock we’ve gone over today…

And why I believe it could roar 1,000% over the next 12 months…

These are the types of investments I share with my readers every month…

The same investments I want to share with you - every time I find a major, game changing opportunity to make money hand over fist.

In short, you get to access a brain that has made millions for myself and for other people during the past three decades.

Which is why I’ve kept the cost of Behind the Markets at the lowest possible level.

However, I am a businessman so I’m not going to make an offer that makes me lose money making this offer to you. That’s why I’m offering you this service for the same amount it costs my business to get this to you.

Anyone can go to our website right now and sign up for our service for just $196!

And frankly, I believe it’s a steal at that price.

The report I’ve promised you today is worth $297 alone.

But more importantly, it’s the opportunity to own a piece of a business that could make investors 100,000% on their money.

Assuming it’s not taken over for a 100% gain first. I don’t know about you, but I’ve been around long enough to know how rare that is.

Look: As I mentioned earlier, this is about feeding more than my wallet. It’s about feeding my soul. And the best way for me to do that is to help as many people as I can.

And I grew up on welfare and food stamps. So I will never forget the value of a dollar.

This report gives you all the details on the amazing company we discussed today.

You’ll learn the name of the company, its stock symbol and why so many of the world’s leading scientists believe its CRISPR technology is the best.

Just this report alone gives investors the chance to ride a medical revolution for potential life-changing gains.

While MAG 7 stocks have been getting all the attention of late, individual investors seem to have forgotten all about the biotech stocks.

In this report we show you exactly how to contrast a bullet-proof biotech portfolio with tremendous upside… an opportunity, my friend, that could make you filthy rich.

But the time you finish this report, you’ll be well on your way to earning life-changing profits in biotech.

The best thing about investing in biotech stocks is that some come with a hidden mechanism that allow you to generate both profits and income.

This report will show you step-by-step exactly how to find the biotech stocks that are primed to give you the biggest upside opportunity – and the most income at the same time.

Learn for yourself how to pick great biotech investments with this simple, yet disciplined, method of identifying the best biologics on the market.

This brief guide will completely familiarize you with the basic concepts behind picking great biotechs and will highlight some of the benefits you’ll see from using them when you trade.

Want to learn how the world’s best biotech companies are changing the world of medicine as we know it?

Go behind the scenes for an in-depth look at how prostate cancer is being treated with the next generation of medicines.

This report will show you step-by-step exactly how new biologic treatments are making the old chemical treatments a thing of the past… and how you can profit from that.

Cannabis stocks are all the rage. But cannabis isn’t the first plant to become a best-selling consumer product in this country.

What lessons does the history of the tobacco industry offer cannabis investors?

In this breakthrough report, we take a look at all the lessons the rise of cigarette companies can teach investors. By the time you finish this report you’ll know which marijuana segments are most likely to succeed and why.

Pretty soon, it will seem like everybody is talking about CRISPR and the gene-editing revolution in general and how much money is going to be made.

And while I don’t doubt that’s true, I’ve been around long enough to know that with every legitimate profit opportunity there will be hustlers trying to take advantage of it. Bernie Madoff, Worldcom and Enron come to mind.

Well, the CRISPR is no different. There will be massive winners – companies like the ones I’ve described to you today. dogs. Companies that talk a good game and promise the world, but that don’t have the infrastructure, technology or management in place to deliver.

This report will show you how to pick the next big winners – and avoid the big losers.

Let me quickly recap what you can expect from
Behind the Markets

Total Value: $1,696!

All available for the low price today of just $49.

That’s because I believe this CRISPR revolution could create as many new millionaires as the Internet did for the tech industry…and I want readers to have the opportunity to make the kind of money that can change the way they live their life.

And it starts with one biotech company at the center of it all.

Those who get in now, on the ground floor, could see the kind of returns Amgen investors saw.

Remember, investors in Amgen started its 47,000% run based on the back of just one drug, Epogen. I believe this company has that kind of potential.

But it pays to act fast. The healthcare sector as a whole is cheaper than its been in a long time. Many of these stocks will look like takeover candidates.

Just click on the orange button below to get started.

This one-in-a-lifetime opportunity is yours for the taking.

I urge you to take advantage of it today.

I look forward to having you on board.

"The Buck Stops Here,"